Rob Davis (Merck)

There’s a new team oc­cu­py­ing the ex­ec­u­tive suite at Mer­ck. And they’ve got a new game plan

Now that Rob Davis and his new­ly re­cruit­ed crew of C-suite ex­ecs are about to take full con­trol of Mer­ck, it’s time to up­date the strat­e­gy man­u­al and fire up some en­thu­si­asm for the phar­ma gi­ant with a re­freshed game plan.

And who bet­ter to get that mes­sage across than sell-side an­a­lysts on Wall Street?

Davis — who tech­ni­cal­ly has to wait un­til Ju­ly 1 to as­sume the ti­tle — and new CFO Car­o­line Litch­field had a vir­tu­al sit-down with a group of an­a­lysts this week to make sure they knew that they were rar­ing to do things…some­what dif­fer­ent­ly. And that in­cludes us­ing a fi­nan­cial wind­fall and stream­lin­ing dri­ve to al­low the BD side to up their game gam­bling while demon­strat­ing a will­ing­ness to tear down the dig­i­tal cur­tain thrown around Phase I and spot­light ear­ly-stage re­search.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.